ProShare Advisors
MRTX

ProShare Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

ProShare Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,482
Closed -$263K – 2042
2023
Q4 		$263K Buy
+4,482
New +$252K ﹤0.01% 1471
2023
Q1 		– Sell
-5,550
Closed -$251K – 1932
2022
Q4 		$251K Buy
5,550
+75
+1% +$4.85K ﹤0.01% 1339
2022
Q3 		$383K Buy
5,475
+331
+6% +$24.5K ﹤0.01% 1017
2022
Q2 		$345K Sell
5,144
-1,733
-25% -$110K ﹤0.01% 1135
2022
Q1 		$565K Sell
6,877
-2,149
-24% -$220K ﹤0.01% 1205
2021
Q4 		$1.32M Sell
9,026
-3,089
-25% -$480K ﹤0.01% 898
2021
Q3 		$2.14M Buy
12,115
+2,872
+31% +$462K 0.01% 701
2021
Q2 		$1.49M Sell
9,243
-9,196
-50% -$1.48M ﹤0.01% 830
2021
Q1 		$3.16M Buy
18,439
+1,204
+7% +$238K 0.01% 564
2020
Q4 		$3.79M Buy
17,235
+5,460
+46% +$1.18M 0.01% 488
2020
Q3 		$1.96M Sell
11,775
-196
-2% -$26.8K 0.01% 575
2020
Q2 		$1.37M Buy
11,971
+4,805
+67% +$466K 0.01% 630
2020
Q1 		$551K Sell
7,166
-5,054
-41% -$453K ﹤0.01% 715
2019
Q4 		$1.57M Sell
12,220
-1,519
-11% -$147K 0.01% 674
2019
Q3 		$1.07M Buy
13,739
+944
+7% +$88.6K 0.01% 726
2019
Q2 		$1.32M Sell
12,795
-1,517
-11% -$118K 0.01% 679
2019
Q1 		$1.05M Buy
14,312
+1,167
+9% +$79.4K 0.01% 737
2018
Q4 		$558K Buy
+13,145
New +$524K ﹤0.01% 914

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ProShare Advisors's MRTX Position: Q1 2024 in Review

ProShare Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,482 shares — an estimated $263K sold.

ProShare Advisors first reported a position in MRTX in Q4 2018 and held it in 18 quarters. The position peaked at $3.79M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • ProShare Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • ProShare Advisors sold 4,482 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $263K.
  • ProShare Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2018 and held it in 18 quarters.
  • ProShare Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $3.79M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on ProShare Advisors's 13F filing for Q1 2024, filed 8 May 2024.